Vor Bio Commences Treatment on Initial Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Shares Company Progress Update.

Evommune Reveals Launch of an Early-Stage Study for Its Novel MRGPRX2 Inhibitor Aimed at Managing Persistent Idiopathic Hives.

PeproMene Bio Announces First Patient in Cohort 1 Achieves Complete Remission in B-ALL Phase 1 Trial with PMB-CT01 at City of Hope.

Immunity Pharma, a clinical-stage neurology specialist, announced positive initial results from its Phase 2a IPL344 trial in ALS patients.

Kairos Pharma, Ltd., specializing in developing new cancer treatments, has started a Phase 1 trial of its leading combination therapy. The study tests their drug ENV105 with osimertinib against non-small cell lung cancer.

Adagene Inc., a leader in antibody therapeutics, shared research at the 2024 ASCO Symposium on Gastrointestinal Cancers in San Francisco.

Regenxbio announces phase II aaviate ® The interim data of the trial were positive. Abbv-rgx-314 administered through sclera was used to treat wet AMD.

Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.

Initial findings from a Phase 1b trial examining treatments with Quemliclustat suggest encouraging survival rates for patients with previously untreated advanced pancreatic cancer.

Vertex Discloses Clearance by the US FDA for CASGEVY™ (exagamglogene autotemcel) as a Therapeutic Option for Beta Thalassemia Patients Requiring Regular Blood Transfusions.

GALDERMA 2024: Phase III trials of RelabotulinumtoxinA show favorable outcomes and extended effectiveness in addressing both glabellar lines and lateral canthal lines at once.

Aviceda Therapeutics Reveals Preliminary Results from Initial Segment of Phase 2/3 SIGLEC Study on AVD-104, Indicating Encouraging Safety Profile and Initial Efficacy Signals in Individuals with Geographic Atrophy.